跳至主要内容
临床试验/NCT05720195
NCT05720195已完成不适用

Assessment of Prognostic Accuracy of Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades in Hepatocellular Carcinoma Patients According to Different Treatment Modalities

Sohag University1 个研究点 分布在 1 个国家目标入组 645 人开始时间: 2019年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
645
试验地点
1
主要终点
Overall survival among HCC patients as assessed by the albumin-bilirubin (ALBI) score

研究概览

简要总结

To compare the predictive ability of ALBI and PALBI grades with CTP and MELD scores.

To investigate the efficacy of ALBI and PALBI grades for predicting the prognosis of HCC and overall survival among different modalities of treatment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The diagnosis of HCC will be based on the presence of an arterial hypervascular focal lesion > 2 cm with rapid wash-out with a single imaging modality (triphasic computed tomography (CT), or dynamic magnetic resonance imaging (MRI)) or two imaging modalities demonstrating the before mentioned feature for lesions < 2 cm with or without elevated serum alpha-fetoprotein (AFP) levels.

排除标准

  • Patients below 18 years old.
  • Patients with pre-existing other malignancies.
  • Patients with pre-existing gall bladder stones, benign strictures, or other biliary diseases.
  • Patients with pre-existing haematologic disorders.
  • Patients with proteinuria.
  • Missed follow-up.

结局指标

主要结局

Overall survival among HCC patients as assessed by the albumin-bilirubin (ALBI) score

时间窗: 2 years

We will compare the ability of ALBI score to predict overall survival among HCC patients versus Child Pugh and MELD scores

Overall survival among HCC patients as assessed by the platelet-albumin-bilirubin (PALBI) score

时间窗: 2 years

We will compare the ability of PALBI score to predict overall survival among HCC patients versus Child Pugh and MELD scores

次要结局

  • Overall survival among HCC patients according to treatment modality as assessed by the albumin-bilirubin (ALBI) score(2 years)
  • Overall survival among HCC patients according to treatment modality as assessed by the platelet-albumin-bilirubin (PALBI)(2 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ahmed Abudeif Abdelaal, MD

Principal investigator

Sohag University

研究点 (1)

Loading locations...

相似试验